<TEXT>&#2;<DATELINE>2006</DATELINE><TITLE>Shifting emphasis from pharmacogenomics to theragnostics</TITLE><BODY>What will be the role of theragnostic patents in upstream and downstream biomarker research?&#3;</BODY></TEXT>